Table 2. Association between sLOX-1 and cardiovascular risk factors.
| Observation | Low LOX-1 (n) | Low LOX-1 (%/Median (IQR)) | High LOX-1 (n) | High LOX-1 (%/Median (IQR)) | P value | Spearman Correlation (rs) | P value (rs) |
|---|---|---|---|---|---|---|---|
| (Group comparison) | |||||||
| Hyperlipidemia | 163 | 7.36% | 99 | 2.02% | 0.09 | ||
| Type-2 diabetes | 163 | 4.29% | 99 | 7.07% | 0.4 | ||
| Statin use | 163 | 13.50% | 99 | 23.23% | 0.06 | ||
| Smoker (Y/N) | 163 | 4.29% | 98 | 8.16% | 0.27 | ||
| BP treated with medication | 163 | 19.02% | 99 | 28.28% | 0.09 | ||
| BP Diastolic | 163 | 71 (64–79) | 99 | 68 (63–76) | 0.04 | -0.04 | 0.52 |
| BP Systolic | 163 | 121 (111–129) | 99 | 121 (109–130) | 0.77 | 0.01 | 0.87 |
| Weight (Kg) | 163 | 67.2 (55.9–87.4) | 99 | 70 (55.9–87.4) | 0.06 | 0.15 | 0.01 |
| Height (CM) | 163 | 159 (156.5–165.4) | 99 | 160.5 (156.5–165.4) | 0.22 | 0.05 | 0.39 |
| BMI | 163 | 25.79 (22.6–29.8) | 99 | 27.71 (22.6–34.1) | 0.07 | 0.15 | 0.02 |
| Total cholesterol [mg/dL] | 163 | 167 (138–193) | 99 | 178 (153–204) | 0.09 | 0.17 | 0.01 |
| LDL [mg/dL] | 163 | 81 (66–97) | 99 | 87 (68–113) | 0.07 | 0.15 | 0.01 |
| FRS Lipids 10-Year Risk | 163 | 2.4 (1.1–4.2) | 98 | 1.8 (0.8–3.6) | 0.11 | -0.05 | 0.39 |
| HDL [mg/dL] | 163 | 59 (47–75) | 99 | 57 (47–69) | 0.62 | -0.01 | 0.84 |
| Triglycerides [mg/dL] | 163 | 92 (73–137) | 99 | 122 (75–166) | 0.02 | 0.22 | 4.00E-04 |
| hsCRP (mg/dL) | 162 | 1.3 (0.7–2.9) | 97 | 2 (1.0–5.5) | 0.01 | 0.25 | 3.07E-05 |
| Adjusted | β value | P value | |||||
| hsCRP (mg/dL) | 162 | 1.3(0.7–2.9) | 97 | 2 (1.0–5.5) | 0.01 | 0.25 | 3.51E-05 |
Multivariate regression analysis for hsCRP and sLOX-1 adjusting for FRS lipids. Adjusted correlation represented as β coefficient (Regression coefficient post standardization of variables dependent and independent variables). BP = blood pressure, hsCRP = high sensitivity C-reactive protein, BMI = Body Mass Index.